De Luca Giuseppe, Algowhary Magdy, Uguz Berat, Oliveira Dinaldo C, Ganyukov Vladimir, Zimbakov Zan, Cercek Miha, Jensen Lisette Okkels, Loh Poay Huan, Calmac Lucian, Roura I Ferrer Gerard, Quadros Alexandre, Milewski Marek, D'Uccio Fortunato Scotto, von Birgelen Clemens, Versaci Francesco, Berg Jurrien Ten, Casella Gianni, Lung Aaron Wong Sung, Kala Petr, Díez Gil José Luis, Carrillo Xavier, Dirksen Maurits, Becerra-Munoz Victor M, Lee Michael Kang-Yin, Juzar Dafsah Arifa, Moura Joaquim Rodrigo de, Paladino Roberto, Milicic Davor, Davlouros Periklis, Bakraceski Nikola, Zilio Filippo, Donazzan Luca, Kraaijeveld Adriaan, Galasso Gennaro, Arpad Lux, Lucia Marinucci, Vincenzo Guiducci, Menichelli Maurizio, Scoccia Alessandra, Yamac Aylin Hatice, Mert Kadir Ugur, Rios Xacobe Flores, Kovarnik Tomas, Kidawa Michal, Moreu Josè, Flavien Vincent, Fabris Enrico, Martínez-Luengas Iñigo Lozano, Ojeda Francisco Bosa, Rodríguez-Sanchez Robert, Caiazzo Gianluca, Cirrincione Giuseppe, Kao Hsien-Li, Forés Juan Sanchis, Vignali Luigi, Pereira Helder, Manzo Stephane, Ordoñez Santiago, Özkan Alev Arat, Scheller Bruno, Lehtola Heidi, Teles Rui, Mantis Christos, Antti Ylitalo, Silveira João António Brum, Zoni Rodrigo, Bessonov Ivan, Savonitto Stefano, Kochiadakis George, Alexopulos Dimitrios, Uribe Carlos E, Kanakakis John, Faurie Benjamin, Gabrielli Gabriele, Gutierrez Barrios Alejandro, Bachini Juan Pablo, Rocha Alex, Tam Frankie Chor-Cheung, Rodriguez Alfredo, Lukito Antonia Anna, Bellemain-Appaix Anne, Pessah Gustavo, Cortese Giuliana, Parodi Guido, Burgadha Mohammed Abed, Kedhi Elvin, Lamelas Pablo, Suryapranata Harry, Nardin Matteo, Verdoia Monica
Division of Cardiology, AOU "Policlinico G. Martino", Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; Division of Cardiology, IRCSS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy.
Division of Cardiology, Assiut University Heart Hospital, Assiut University, Asyut, Egypt.
Nutr Metab Cardiovasc Dis. 2025 May;35(5):103763. doi: 10.1016/j.numecd.2024.09.031. Epub 2024 Oct 24.
Diabetes has been shown in last decades to be associated with a significantly higher mortality among patients with ST-segment elevation myocardial infarction (STEMI) treated with primary PCI (PPCI). Therefore, the aim of current study was to evaluate the impact of diabetes on times delays, reperfusion and mortality in a contemporary STEMI population undergoing PPCI, including treatment during the COVID pandemic.
The ISACS-STEMI COVID-19 is a large-scale retrospective multicenter registry involving PPCI centers from Europe, Latin America, South-East Asia and North-Africa, including patients treated from 1st of March until June 30, 2019 and 2020. Primary study endpoint of this analysis was in-hospital mortality. Secondary endpoints were postprocedural TIMI 0-2 flow and 30-day mortality. Our population is represented by 16083 STEMI patients. A total of 3812 (23,7 %) patients suffered from diabetes. They were older, more often males as compared to non-diabetes. Diabetic patients were less often active smokers and had less often a positive family history of CAD, but they were more often affected by hypertension and hypercholesterolemia, with higher prevalence of previous STEMI and previous CABG. Diabetic patients had longer ischemia time, had more often anterior MI, cardiogenic shock, rescue PCI and multivessel disease. They had less often out-of-hospital cardiac arrest and in-stent thrombosis, received more often a mechanical support, received less often a coronary stent and DES. Diabetes was associated with a significantly impaired postprocedural TIMI flow (TIMI 0-2: 9.8 % vs 7.2 %, adjusted OR [95 % CI] = 1.17 [1.02-1.38], p = 0.024) and higher mortality (in-hospital: 9.1 % vs 4.8 %, Adjusted OR [95 % CI] = 1.70 [1.43-2.02], p < 0.001; 30-day mortality: 10.8 % vs 6 %, Adjusted HR [95 % CI] = 1.46 [1.26-1.68], p < 0.001) as compared to non-diabetes, particularly during the pandemic.
Our study showed that in a contemporary STEMI population undergoing PPCI, diabetes is significantly associated with impaired epicardial reperfusion that translates into higher in-hospital and 30-day mortality, particularly during the pandemic.
在过去几十年中,已证实糖尿病与接受直接经皮冠状动脉介入治疗(PPCI)的ST段抬高型心肌梗死(STEMI)患者的死亡率显著升高相关。因此,本研究的目的是评估糖尿病对当代接受PPCI的STEMI患者的时间延迟、再灌注和死亡率的影响,包括在新冠疫情期间的治疗情况。
ISACS-STEMI COVID-19是一项大规模回顾性多中心注册研究,涉及来自欧洲、拉丁美洲、东南亚和北非的PPCI中心,纳入了2019年3月1日至2020年6月30日期间接受治疗的患者。该分析的主要研究终点是住院死亡率。次要终点是术后心肌梗死溶栓治疗(TIMI)0至2级血流以及30天死亡率。我们的研究人群包括16083例STEMI患者。共有3812例(23.7%)患者患有糖尿病。与非糖尿病患者相比,他们年龄更大,男性更常见。糖尿病患者主动吸烟者较少,冠心病家族史阳性者也较少,但他们更常患高血压和高胆固醇血症,既往STEMI和既往冠状动脉旁路移植术(CABG)的患病率更高。糖尿病患者缺血时间更长,前壁心肌梗死、心源性休克、补救性PCI和多支血管病变更常见。他们院外心脏骤停和支架内血栓形成较少见,接受机械支持更频繁,接受冠状动脉支架和药物洗脱支架(DES)较少。与非糖尿病患者相比,糖尿病与术后TIMI血流显著受损相关(TIMI 0至2级:9.8%对7.2%,调整后比值比[95%置信区间]=1.17[1.02 - 1.38],p = 0.024),且死亡率更高(住院死亡率:9.1%对4.8%,调整后比值比[95%置信区间]=1.70[1.43 - 2.02],p < 0.001;30天死亡率:10.8%对6%,调整后风险比[95%置信区间]=1.46[1.26 - 1.68],p < 0.001),尤其是在疫情期间。
我们的研究表明,在当代接受PPCI的STEMI患者中,糖尿病与心外膜再灌注受损显著相关,这导致更高的住院死亡率和30天死亡率,尤其是在疫情期间